{
    "info": {
        "nct_id": "NCT06085079",
        "official_title": "A 24-week Two-armed Proof-of-concept Exploratory Analysis of Subcutaneous Ixekizumab Administration in Patients With Recalcitrant Non-infectious Intermediate, Posterior, Panuveitis, or Chronic Steroid-dependent Anterior Uveitis.",
        "inclusion_criteria": "1. At least 18 years of age\n2. Diagnosis of non-infectious intermediate, posterior, panuveitis, or chronic steroid dependent anterior uveitis\n3. Failure of at least one classic synthetic DMARD including Methotrexate, Mycophenolate, Cyclosporin, Azathioprine, Cyclophosphamide, and/or at least one anti-TNF agent including Adalimumab, Infliximab, Etanercept, Golimumab or Certolizumab\n4. Active disease at screening visit\n5. At least 1 of the following parameters in at least one eye:\n\n   * active inflammatory chorioretinal and/or inflammatory retinal vascular lesions\n   * ≥ 1+ vitreous haze (Nussenblatt criteria)\n   * ≥ 2+ anterior chamber cells (National Eye Institute/Standardization of Uveitis Nomenclature criteria)\n   * Cystoid macular edema, seen on optical coherence tomography and/or fluorescein angiography\n   * FA leakage pattern deemed by investigators to be suggestive of active intermediate, posterior, and panuveitis, including optic disc, retinal vascular, and macular leakages\n   * Active snowbanking\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* The presence of only acute anterior uveitis.\n* Serpiginous choroidopathy\n* Subject with prior inadequate response to high-dose oral corticosteroids (> 60 mg of prednisone)\n* Subject with confirmed or suspected infectious uveitis\n* Patients with intraocular pressure of ≥ 25 mmHg or evidence of optic nerve injury\n* Corneal or lens opacity that precludes adequate ophthalmic evaluation.\n* Patients likely to undergo cataract surgery during the duration of the trial.\n* Patients with Best Corrected Visual Acuity (BCVA) less than 20 letters (Early Treatment Diabetic Retinopathy Study)\n* Dose of concomitant immunosuppressive therapy at the baseline visit:\n\n  * Methotrexate (MTX) ˃ 25 mg per week\n  * Cyclosporine ˃ 4 mg/kg per day\n  * Mycophenolate mofetil ˃ 3 grams per day or an equivalent drug to mycophenolate mofetil (e.g. mycophenolic acid) at an equivalent dose approved by the medical monitor.\n  * Azathioprine ˃ 175 mg per day\n  * Tacrolimus (oral formulation) > 8 mg per day\n* If entering the study on 1 concomitant immunosuppressive therapy, dose has been increased within the last 28 days prior to Baseline visit.\n* Subject has received Retisert® (implant) within 3 years prior to the Baseline visit or that has had complications related to the device. Subject has had Retisert® (implant) removed within 90 days prior to the Baseline visit or has had complications related to the removal of the device\n* Subject has received intraocular or periocular corticosteroids within 30 days prior to Baseline visit\n* Subject with proliferative or severe non-proliferative diabetic retinopathy or clinically significant macular edema due to diabetic retinopathy\n* Subject with neovascular/wet age-related macular degeneration\n* Subject with abnormality of vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.) with the potential for macular structural damage independent of the inflammatory process, deemed macular pathology is deemed by a retinal specialist to be a potential cofounder of patient's visual acuity reduction\n* Subject with severe vitreous haze that precludes visualization of the fundus at the baseline visit\n* Subject has received Ozurdex® (dexamethasone implant) within 6 months prior to the baseline visit\n* Subject has received intravitreal anti-VEGF therapy within 45 days of the Baseline visit for Lucentis® (ranibizumab) or Avastin® (bevacizumab) or within 60 days of the Baseline visit for anti-VEGF Trap (aflibercept)\n* Subject has received intravitreal methotrexate within 90 days prior to the Baseline visit\n* Subject on systemic carbonic anhydrase inhibitor within 1 week prior to Screening visit\n* Subject with macular edema as the only sign of uveitis\n* Subject with a history of scleritis\n* Subject with intolerance to high-dose oral corticosteroids (equivalent of oral prednisone 1 mg/kg/day or 60 to 80 mg/day)\n* Subject on cyclophosphamide within 30 days prior to the Baseline visit\n* Participation in other investigational drug or device clinical trials within 30 days prior to Day 0 or planning to participate in other investigational drug or device clinical trials within 180 days following 48 weeks after day 0. This includes both ocular and non-ocular clinical trials\n* Major surgery within 8 weeks prior to screening or planned major surgery within 6 months following randomization\n* Treatment with intravenous gamma globulin or plasmapheresis during the course of the trial\n* Immunization with a live/attenuated vaccine within 4 weeks prior to baseline\n* History of severe allergic or anaphylactic reactions to human, humanized monoclonal antibodies\n* Prior history of Crohn's Colitis or Ulcerative Colitis\n* Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (include uncontrolled diabetes mellitus) or gastrointestinal disease (including complicated diverticulitis, liver disease or peptic ulcer disease)\n* Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, Hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds)\n* Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening\n* Active tuberculosis (TB) requiring treatment within the previous 3 years. Patients should be screened for latent TB and, if positive, treated following local practice guidelines prior to initiating trial. Patients treated for tuberculosis with no recurrence in 3 years are permitted\n* Primary or secondary immunodeficiency (history of or currently active)\n* Evidence of active malignant disease, malignancies diagnosed within the previous 5 years (including hematological malignancies and solid tumors, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured)\n* Pregnant women or breast-feeding mothers\n* Patients with reproductive potential not willing to use an effective method of contraception\n* History of alcohol, drug, or chemical abuse within 1 year prior to screening.\n* Serum creatinine > 1.6 mg/dL (141 μmol/L) in female patients and > 1.9 mg/dL (168 μmol/L) in male patients. Patients with serum creatinine values exceeding limits may be eligible for the study if their estimated glomerular filtration rates (GFR) are >30.\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 times upper limit of normal (ULN)\n* Total Bilirubin > 1.5 ULN\n* Platelet count < 100 x 109/L (100,000/mm3)\n* Hemoglobin < 85 g/L (8.5 g/dL; 5.3 mmol/L)\n* White Blood Cells < 3.0 x 109/L (3000/mm3)\n* Absolute Neutrophil Count < 2.0 x 109/L (2000/mm3)\n* Absolute Lymphocyte Count < 0.5 x 109/L (500/mm3)\n* Positive Hepatitis BsAg, or Hepatitis C antibody",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. At least 1 of the following parameters in at least one eye:",
            "criterions": [
                {
                    "exact_snippets": "At least 1 of the following parameters in at least one eye",
                    "criterion": "parameters in eye",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "parameter(s)"
                            }
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "at least one eye"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active snowbanking",
            "criterions": [
                {
                    "exact_snippets": "Active snowbanking",
                    "criterion": "snowbanking",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. At least 18 years of age",
            "criterions": [
                {
                    "exact_snippets": "At least 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥ 2+ anterior chamber cells (National Eye Institute/Standardization of Uveitis Nomenclature criteria)",
            "criterions": [
                {
                    "exact_snippets": "≥ 2+ anterior chamber cells (National Eye Institute/Standardization of Uveitis Nomenclature criteria)",
                    "criterion": "anterior chamber cells",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "+"
                            }
                        },
                        {
                            "requirement_type": "measurement_standard",
                            "expected_value": "National Eye Institute/Standardization of Uveitis Nomenclature criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥ 1+ vitreous haze (Nussenblatt criteria)",
            "criterions": [
                {
                    "exact_snippets": "≥ 1+ vitreous haze (Nussenblatt criteria)",
                    "criterion": "vitreous haze (Nussenblatt criteria)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "+"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cystoid macular edema, seen on optical coherence tomography and/or fluorescein angiography",
            "criterions": [
                {
                    "exact_snippets": "Cystoid macular edema",
                    "criterion": "cystoid macular edema",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "seen on optical coherence tomography",
                    "criterion": "cystoid macular edema on optical coherence tomography",
                    "requirements": [
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "optical coherence tomography"
                        }
                    ]
                },
                {
                    "exact_snippets": "seen on ... fluorescein angiography",
                    "criterion": "cystoid macular edema on fluorescein angiography",
                    "requirements": [
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "fluorescein angiography"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* active inflammatory chorioretinal and/or inflammatory retinal vascular lesions",
            "criterions": [
                {
                    "exact_snippets": "active inflammatory chorioretinal ... lesions",
                    "criterion": "inflammatory chorioretinal lesions",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "active ... inflammatory retinal vascular lesions",
                    "criterion": "inflammatory retinal vascular lesions",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* FA leakage pattern deemed by investigators to be suggestive of active intermediate, posterior, and panuveitis, including optic disc, retinal vascular, and macular leakages",
            "criterions": [
                {
                    "exact_snippets": "FA leakage pattern deemed by investigators to be suggestive of active intermediate, posterior, and panuveitis",
                    "criterion": "FA leakage pattern",
                    "requirements": [
                        {
                            "requirement_type": "suggestive of",
                            "expected_value": [
                                "active intermediate uveitis",
                                "active posterior uveitis",
                                "active panuveitis"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "including optic disc, retinal vascular, and macular leakages",
                    "criterion": "leakage location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "optic disc",
                                "retinal vascular",
                                "macular"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Active disease at screening visit",
            "criterions": [
                {
                    "exact_snippets": "Active disease at screening visit",
                    "criterion": "active disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at screening visit"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Diagnosis of non-infectious intermediate, posterior, panuveitis, or chronic steroid dependent anterior uveitis",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of non-infectious intermediate, posterior, panuveitis, or chronic steroid dependent anterior uveitis",
                    "criterion": "uveitis diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "non-infectious intermediate uveitis",
                                "non-infectious posterior uveitis",
                                "non-infectious panuveitis",
                                "chronic steroid dependent anterior uveitis"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Failure of at least one classic synthetic DMARD including Methotrexate, Mycophenolate, Cyclosporin, Azathioprine, Cyclophosphamide, and/or at least one anti-TNF agent including Adalimumab, Infliximab, Etanercept, Golimumab or Certolizumab",
            "criterions": [
                {
                    "exact_snippets": "Failure of at least one classic synthetic DMARD including Methotrexate, Mycophenolate, Cyclosporin, Azathioprine, Cyclophosphamide",
                    "criterion": "classic synthetic DMARD treatment",
                    "requirements": [
                        {
                            "requirement_type": "failure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of agents failed",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "agent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one anti-TNF agent including Adalimumab, Infliximab, Etanercept, Golimumab or Certolizumab",
                    "criterion": "anti-TNF agent treatment",
                    "requirements": [
                        {
                            "requirement_type": "failure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of agents failed",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "agent"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Subject with neovascular/wet age-related macular degeneration",
            "criterions": [
                {
                    "exact_snippets": "Subject with neovascular/wet age-related macular degeneration",
                    "criterion": "neovascular/wet age-related macular degeneration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients likely to undergo cataract surgery during the duration of the trial.",
            "criterions": [
                {
                    "exact_snippets": "Patients likely to undergo cataract surgery during the duration of the trial",
                    "criterion": "likelihood of undergoing cataract surgery",
                    "requirements": [
                        {
                            "requirement_type": "likelihood",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during the duration of the trial"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* White Blood Cells < 3.0 x 109/L (3000/mm3)",
            "criterions": [
                {
                    "exact_snippets": "White Blood Cells < 3.0 x 109/L (3000/mm3)",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3.0,
                                "unit": "x 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3000,
                                "unit": "mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Primary or secondary immunodeficiency (history of or currently active)",
            "criterions": [
                {
                    "exact_snippets": "Primary or secondary immunodeficiency (history of or currently active)",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "primary",
                                "secondary"
                            ]
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "history of",
                                "currently active"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute Neutrophil Count < 2.0 x 109/L (2000/mm3)",
            "criterions": [
                {
                    "exact_snippets": "Absolute Neutrophil Count < 2.0 x 109/L (2000/mm3)",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": "x 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2000,
                                "unit": "mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject with intolerance to high-dose oral corticosteroids (equivalent of oral prednisone 1 mg/kg/day or 60 to 80 mg/day)",
            "criterions": [
                {
                    "exact_snippets": "intolerance to high-dose oral corticosteroids (equivalent of oral prednisone 1 mg/kg/day or 60 to 80 mg/day)",
                    "criterion": "intolerance to high-dose oral corticosteroids",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "equivalent of oral prednisone 1 mg/kg/day or 60 to 80 mg/day",
                    "criterion": "oral prednisone dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 60,
                                        "unit": "mg/day"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 80,
                                        "unit": "mg/day"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "mg/kg/day"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positive Hepatitis BsAg, or Hepatitis C antibody",
            "criterions": [
                {
                    "exact_snippets": "Positive Hepatitis BsAg",
                    "criterion": "Hepatitis BsAg",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatitis C antibody",
                    "criterion": "Hepatitis C antibody",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening",
            "criterions": [
                {
                    "exact_snippets": "Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening",
                    "criterion": "major episode of infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "hospitalization",
                                "IV antibiotics"
                            ]
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Any major episode of infection requiring ... oral antibiotics within 2 weeks prior to screening",
                    "criterion": "major episode of infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": "oral antibiotics"
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cyclosporine ˃ 4 mg/kg per day",
            "criterions": [
                {
                    "exact_snippets": "Cyclosporine ˃ 4 mg/kg per day",
                    "criterion": "Cyclosporine dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "mg/kg per day"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 times upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... > 1.5 times upper limit of normal (ULN)",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "times ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) > 1.5 times upper limit of normal (ULN)",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "times ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with Best Corrected Visual Acuity (BCVA) less than 20 letters (Early Treatment Diabetic Retinopathy Study)",
            "criterions": [
                {
                    "exact_snippets": "Best Corrected Visual Acuity (BCVA) less than 20 letters (Early Treatment Diabetic Retinopathy Study)",
                    "criterion": "Best Corrected Visual Acuity (BCVA)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 20,
                                "unit": "letters (ETDRS)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The presence of only acute anterior uveitis.",
            "criterions": [
                {
                    "exact_snippets": "The presence of only acute anterior uveitis",
                    "criterion": "acute anterior uveitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exclusivity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant women or breast-feeding mothers",
            "criterions": [
                {
                    "exact_snippets": "Pregnant women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breast-feeding mothers",
                    "criterion": "breast-feeding status",
                    "requirements": [
                        {
                            "requirement_type": "breast-feeding",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of alcohol, drug, or chemical abuse within 1 year prior to screening.",
            "criterions": [
                {
                    "exact_snippets": "History of alcohol ... abuse within 1 year prior to screening.",
                    "criterion": "alcohol abuse",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year prior to screening"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... drug ... abuse within 1 year prior to screening.",
                    "criterion": "drug abuse",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year prior to screening"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... chemical abuse within 1 year prior to screening.",
                    "criterion": "chemical abuse",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year prior to screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject with abnormality of vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.) with the potential for macular structural damage independent of the inflammatory process, deemed macular pathology is deemed by a retinal specialist to be a potential cofounder of patient's visual acuity reduction",
            "criterions": [
                {
                    "exact_snippets": "abnormality of vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.)",
                    "criterion": "vitreo-retinal interface abnormality",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "potential for macular structural damage independent of the inflammatory process",
                    "criterion": "macular structural damage potential (independent of inflammatory process)",
                    "requirements": [
                        {
                            "requirement_type": "potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "macular pathology is deemed by a retinal specialist to be a potential cofounder of patient's visual acuity reduction",
                    "criterion": "macular pathology as confounder for visual acuity reduction",
                    "requirements": [
                        {
                            "requirement_type": "assessment by retinal specialist",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "potential confounder for visual acuity reduction",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject with proliferative or severe non-proliferative diabetic retinopathy or clinically significant macular edema due to diabetic retinopathy",
            "criterions": [
                {
                    "exact_snippets": "proliferative ... diabetic retinopathy",
                    "criterion": "diabetic retinopathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "proliferative"
                        }
                    ]
                },
                {
                    "exact_snippets": "severe non-proliferative diabetic retinopathy",
                    "criterion": "diabetic retinopathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe non-proliferative"
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant macular edema due to diabetic retinopathy",
                    "criterion": "macular edema",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "diabetic retinopathy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has received Retisert® (implant) within 3 years prior to the Baseline visit or that has had complications related to the device. Subject has had Retisert® (implant) removed within 90 days prior to the Baseline visit or has had complications related to the removal of the device",
            "criterions": [
                {
                    "exact_snippets": "Subject has received Retisert® (implant) within 3 years prior to the Baseline visit",
                    "criterion": "Retisert® (implant) administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "reference event",
                            "expected_value": "Baseline visit"
                        }
                    ]
                },
                {
                    "exact_snippets": "has had complications related to the device",
                    "criterion": "complications related to Retisert® (implant)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subject has had Retisert® (implant) removed within 90 days prior to the Baseline visit",
                    "criterion": "Retisert® (implant) removal",
                    "requirements": [
                        {
                            "requirement_type": "time since removal",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "reference event",
                            "expected_value": "Baseline visit"
                        }
                    ]
                },
                {
                    "exact_snippets": "has had complications related to the removal of the device",
                    "criterion": "complications related to Retisert® (implant) removal",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corneal or lens opacity that precludes adequate ophthalmic evaluation.",
            "criterions": [
                {
                    "exact_snippets": "Corneal or lens opacity that precludes adequate ophthalmic evaluation",
                    "criterion": "corneal opacity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "precludes adequate ophthalmic evaluation"
                        }
                    ]
                },
                {
                    "exact_snippets": "Corneal or lens opacity that precludes adequate ophthalmic evaluation",
                    "criterion": "lens opacity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "precludes adequate ophthalmic evaluation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (include uncontrolled diabetes mellitus) or gastrointestinal disease (including complicated diverticulitis, liver disease or peptic ulcer disease)",
            "criterions": [
                {
                    "exact_snippets": "serious uncontrolled concomitant cardiovascular ... disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                },
                {
                    "exact_snippets": "serious uncontrolled concomitant ... nervous system ... disease",
                    "criterion": "nervous system disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                },
                {
                    "exact_snippets": "serious uncontrolled concomitant ... pulmonary (including obstructive pulmonary disease) ... disease",
                    "criterion": "pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                },
                {
                    "exact_snippets": "obstructive pulmonary disease",
                    "criterion": "obstructive pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "serious uncontrolled concomitant ... renal ... disease",
                    "criterion": "renal disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                },
                {
                    "exact_snippets": "serious uncontrolled concomitant ... hepatic ... disease",
                    "criterion": "hepatic disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                },
                {
                    "exact_snippets": "serious uncontrolled concomitant ... endocrine (include uncontrolled diabetes mellitus) ... disease",
                    "criterion": "endocrine disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled diabetes mellitus",
                    "criterion": "diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "serious uncontrolled concomitant ... gastrointestinal disease (including complicated diverticulitis, liver disease or peptic ulcer disease)",
                    "criterion": "gastrointestinal disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                },
                {
                    "exact_snippets": "complicated diverticulitis",
                    "criterion": "diverticulitis",
                    "requirements": [
                        {
                            "requirement_type": "complication status",
                            "expected_value": "complicated"
                        }
                    ]
                },
                {
                    "exact_snippets": "liver disease",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "peptic ulcer disease",
                    "criterion": "peptic ulcer disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tacrolimus (oral formulation) > 8 mg per day",
            "criterions": [
                {
                    "exact_snippets": "Tacrolimus (oral formulation) > 8 mg per day",
                    "criterion": "oral tacrolimus dosage",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "mg per day"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior history of Crohn's Colitis or Ulcerative Colitis",
            "criterions": [
                {
                    "exact_snippets": "Prior history of Crohn's Colitis or Ulcerative Colitis",
                    "criterion": "Crohn's Colitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior history of Crohn's Colitis or Ulcerative Colitis",
                    "criterion": "Ulcerative Colitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 8 weeks prior to screening or planned major surgery within 6 months following randomization",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 8 weeks prior to screening",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery before screening",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "planned major surgery within 6 months following randomization",
                    "criterion": "planned major surgery",
                    "requirements": [
                        {
                            "requirement_type": "planned timing after randomization",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunization with a live/attenuated vaccine within 4 weeks prior to baseline",
            "criterions": [
                {
                    "exact_snippets": "Immunization with a live/attenuated vaccine within 4 weeks prior to baseline",
                    "criterion": "immunization with a live/attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to baseline"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has received Ozurdex® (dexamethasone implant) within 6 months prior to the baseline visit",
            "criterions": [
                {
                    "exact_snippets": "Subject has received Ozurdex® (dexamethasone implant) within 6 months prior to the baseline visit",
                    "criterion": "Ozurdex (dexamethasone implant) administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "relative to baseline visit",
                            "expected_value": "prior"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total Bilirubin > 1.5 ULN",
            "criterions": [
                {
                    "exact_snippets": "Total Bilirubin > 1.5 ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with intraocular pressure of ≥ 25 mmHg or evidence of optic nerve injury",
            "criterions": [
                {
                    "exact_snippets": "intraocular pressure of ≥ 25 mmHg",
                    "criterion": "intraocular pressure",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of optic nerve injury",
                    "criterion": "optic nerve injury",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject with macular edema as the only sign of uveitis",
            "criterions": [
                {
                    "exact_snippets": "macular edema as the only sign of uveitis",
                    "criterion": "macular edema",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "macular edema as the only sign of uveitis",
                    "criterion": "other signs of uveitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participation in other investigational drug or device clinical trials within 30 days prior to Day 0 or planning to participate in other investigational drug or device clinical trials within 180 days following 48 weeks after day 0. This includes both ocular and non-ocular clinical trials",
            "criterions": [
                {
                    "exact_snippets": "Participation in other investigational drug or device clinical trials within 30 days prior to Day 0",
                    "criterion": "participation in other investigational drug or device clinical trials",
                    "requirements": [
                        {
                            "requirement_type": "time window prior to Day 0",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "planning to participate in other investigational drug or device clinical trials within 180 days following 48 weeks after day 0",
                    "criterion": "planned participation in other investigational drug or device clinical trials",
                    "requirements": [
                        {
                            "requirement_type": "time window after 48 weeks post Day 0",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with reproductive potential not willing to use an effective method of contraception",
            "criterions": [
                {
                    "exact_snippets": "Patients with reproductive potential",
                    "criterion": "reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not willing to use an effective method of contraception",
                    "criterion": "contraception use willingness",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use effective contraception",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serpiginous choroidopathy",
            "criterions": [
                {
                    "exact_snippets": "Serpiginous choroidopathy",
                    "criterion": "serpiginous choroidopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Dose of concomitant immunosuppressive therapy at the baseline visit:",
            "criterions": [
                {
                    "exact_snippets": "Dose of concomitant immunosuppressive therapy at the baseline visit",
                    "criterion": "concomitant immunosuppressive therapy dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "specified at baseline visit"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine > 1.6 mg/dL (141 μmol/L) in female patients and > 1.9 mg/dL (168 μmol/L) in male patients. Patients with serum creatinine values exceeding limits may be eligible for the study if their estimated glomerular filtration rates (GFR) are >30.",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine > 1.6 mg/dL (141 μmol/L) in female patients",
                    "criterion": "serum creatinine (female)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.6,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 141,
                                "unit": "μmol/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Serum creatinine ... > 1.9 mg/dL (168 μmol/L) in male patients",
                    "criterion": "serum creatinine (male)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.9,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 168,
                                "unit": "μmol/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with serum creatinine values exceeding limits may be eligible ... if their estimated glomerular filtration rates (GFR) are >30",
                    "criterion": "estimated glomerular filtration rate (GFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject with a history of scleritis",
            "criterions": [
                {
                    "exact_snippets": "history of scleritis",
                    "criterion": "scleritis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If entering the study on 1 concomitant immunosuppressive therapy, dose has been increased within the last 28 days prior to Baseline visit.",
            "criterions": [
                {
                    "exact_snippets": "entering the study on 1 concomitant immunosuppressive therapy",
                    "criterion": "concomitant immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of therapies",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "dose has been increased within the last 28 days prior to Baseline visit",
                    "criterion": "immunosuppressive therapy dose",
                    "requirements": [
                        {
                            "requirement_type": "dose change",
                            "expected_value": "increased"
                        },
                        {
                            "requirement_type": "time since dose increase",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin < 85 g/L (8.5 g/dL; 5.3 mmol/L)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin < 85 g/L (8.5 g/dL; 5.3 mmol/L)",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 85,
                                "unit": "g/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Methotrexate (MTX) ˃ 25 mg per week",
            "criterions": [
                {
                    "exact_snippets": "Methotrexate (MTX) ˃ 25 mg per week",
                    "criterion": "Methotrexate (MTX) dosage",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 25,
                                "unit": "mg per week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active tuberculosis (TB) requiring treatment within the previous 3 years. Patients should be screened for latent TB and, if positive, treated following local practice guidelines prior to initiating trial. Patients treated for tuberculosis with no recurrence in 3 years are permitted",
            "criterions": [
                {
                    "exact_snippets": "Active tuberculosis (TB) requiring treatment within the previous 3 years",
                    "criterion": "active tuberculosis (TB)",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement within previous 3 years",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients should be screened for latent TB",
                    "criterion": "latent tuberculosis (TB)",
                    "requirements": [
                        {
                            "requirement_type": "screening",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if positive, treated following local practice guidelines prior to initiating trial",
                    "criterion": "latent tuberculosis (TB)",
                    "requirements": [
                        {
                            "requirement_type": "treatment if positive",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients treated for tuberculosis with no recurrence in 3 years are permitted",
                    "criterion": "tuberculosis recurrence",
                    "requirements": [
                        {
                            "requirement_type": "recurrence within 3 years",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has received intraocular or periocular corticosteroids within 30 days prior to Baseline visit",
            "criterions": [
                {
                    "exact_snippets": "received intraocular or periocular corticosteroids within 30 days prior to Baseline visit",
                    "criterion": "intraocular or periocular corticosteroid administration",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to Baseline visit"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of active malignant disease, malignancies diagnosed within the previous 5 years (including hematological malignancies and solid tumors, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured)",
            "criterions": [
                {
                    "exact_snippets": "Evidence of active malignant disease",
                    "criterion": "active malignant disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "malignancies diagnosed within the previous 5 years",
                    "criterion": "malignancy diagnosis timing",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured",
                    "criterion": "type of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "basal cell carcinoma of the skin (excised and cured)",
                                "squamous cell carcinoma of the skin (excised and cured)",
                                "carcinoma in situ of the cervix uteri (excised and cured)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject on systemic carbonic anhydrase inhibitor within 1 week prior to Screening visit",
            "criterions": [
                {
                    "exact_snippets": "Subject on systemic carbonic anhydrase inhibitor within 1 week prior to Screening visit",
                    "criterion": "systemic carbonic anhydrase inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "week prior to Screening visit"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject on cyclophosphamide within 30 days prior to the Baseline visit",
            "criterions": [
                {
                    "exact_snippets": "Subject on cyclophosphamide within 30 days prior to the Baseline visit",
                    "criterion": "cyclophosphamide use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to Baseline visit"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Mycophenolate mofetil ˃ 3 grams per day or an equivalent drug to mycophenolate mofetil (e.g. mycophenolic acid) at an equivalent dose approved by the medical monitor.",
            "criterions": [
                {
                    "exact_snippets": "Mycophenolate mofetil ˃ 3 grams per day",
                    "criterion": "mycophenolate mofetil dosage",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "grams per day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "an equivalent drug to mycophenolate mofetil (e.g. mycophenolic acid) at an equivalent dose approved by the medical monitor",
                    "criterion": "equivalent drug to mycophenolate mofetil dosage",
                    "requirements": [
                        {
                            "requirement_type": "drug_equivalence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose_approval",
                            "expected_value": "approved by the medical monitor"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with intravenous gamma globulin or plasmapheresis during the course of the trial",
            "criterions": [
                {
                    "exact_snippets": "Treatment with intravenous gamma globulin ... during the course of the trial",
                    "criterion": "intravenous gamma globulin treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment during trial",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... plasmapheresis during the course of the trial",
                    "criterion": "plasmapheresis treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment during trial",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe allergic or anaphylactic reactions to human, humanized monoclonal antibodies",
            "criterions": [
                {
                    "exact_snippets": "History of severe allergic or anaphylactic reactions to human, humanized monoclonal antibodies",
                    "criterion": "severe allergic or anaphylactic reactions to human, humanized monoclonal antibodies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject with severe vitreous haze that precludes visualization of the fundus at the baseline visit",
            "criterions": [
                {
                    "exact_snippets": "severe vitreous haze that precludes visualization of the fundus at the baseline visit",
                    "criterion": "vitreous haze",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "effect on visualization of the fundus",
                            "expected_value": "precludes visualization"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the baseline visit"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Azathioprine ˃ 175 mg per day",
            "criterions": [
                {
                    "exact_snippets": "Azathioprine ˃ 175 mg per day",
                    "criterion": "Azathioprine dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 175,
                                "unit": "mg per day"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject with confirmed or suspected infectious uveitis",
            "criterions": [
                {
                    "exact_snippets": "confirmed or suspected infectious uveitis",
                    "criterion": "infectious uveitis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": [
                                "confirmed",
                                "suspected"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, Hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds)",
            "criterions": [
                {
                    "exact_snippets": "Known active current or history of recurrent bacterial ... infections (including but not limited to ... tuberculosis and atypical mycobacterial disease, Hepatitis B and C, and herpes zoster",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "activity or history",
                            "expected_value": [
                                "active",
                                "current",
                                "history of recurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Known active current or history of recurrent ... viral ... infections (including but not limited to ... Hepatitis B and C, and herpes zoster",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "activity or history",
                            "expected_value": [
                                "active",
                                "current",
                                "history of recurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Known active current or history of recurrent ... fungal ... infections (including but not limited to ... but excluding fungal infections of nail beds",
                    "criterion": "fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "activity or history",
                            "expected_value": [
                                "active",
                                "current",
                                "history of recurrent"
                            ]
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "excluding nail beds"
                        }
                    ]
                },
                {
                    "exact_snippets": "Known active current or history of recurrent ... mycobacterial ... infections (including but not limited to tuberculosis and atypical mycobacterial disease",
                    "criterion": "mycobacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "activity or history",
                            "expected_value": [
                                "active",
                                "current",
                                "history of recurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Known active current or history of recurrent ... other infections",
                    "criterion": "other infection",
                    "requirements": [
                        {
                            "requirement_type": "activity or history",
                            "expected_value": [
                                "active",
                                "current",
                                "history of recurrent"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject with prior inadequate response to high-dose oral corticosteroids (> 60 mg of prednisone)",
            "criterions": [
                {
                    "exact_snippets": "prior inadequate response to high-dose oral corticosteroids (> 60 mg of prednisone)",
                    "criterion": "response to high-dose oral corticosteroids",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": "inadequate"
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 60,
                                "unit": "mg of prednisone"
                            }
                        },
                        {
                            "requirement_type": "prior",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has received intravitreal methotrexate within 90 days prior to the Baseline visit",
            "criterions": [
                {
                    "exact_snippets": "received intravitreal methotrexate within 90 days prior to the Baseline visit",
                    "criterion": "intravitreal methotrexate administration",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days prior to Baseline visit"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Absolute Lymphocyte Count < 0.5 x 109/L (500/mm3)",
            "criterions": [
                {
                    "exact_snippets": "Absolute Lymphocyte Count < 0.5 x 10^9/L (500/mm3)",
                    "criterion": "absolute lymphocyte count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 0.5,
                                "unit": "10^9/L"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 500,
                                "unit": "mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count < 100 x 109/L (100,000/mm3)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count < 100 x 10^9/L (100,000/mm3)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has received intravitreal anti-VEGF therapy within 45 days of the Baseline visit for Lucentis® (ranibizumab) or Avastin® (bevacizumab) or within 60 days of the Baseline visit for anti-VEGF Trap (aflibercept)",
            "criterions": [
                {
                    "exact_snippets": "received intravitreal anti-VEGF therapy within 45 days of the Baseline visit for Lucentis® (ranibizumab) or Avastin® (bevacizumab)",
                    "criterion": "intravitreal anti-VEGF therapy (Lucentis or Avastin)",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 45,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "drug",
                            "expected_value": [
                                "Lucentis (ranibizumab)",
                                "Avastin (bevacizumab)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "received intravitreal anti-VEGF therapy within 60 days of the Baseline visit for anti-VEGF Trap (aflibercept)",
                    "criterion": "intravitreal anti-VEGF therapy (aflibercept)",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "drug",
                            "expected_value": "aflibercept"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}